Morphine pharmacokinetics and metabolism in humans : enterohepatic cycling and relative contribution of metabolites to active opioid concentrations
Morphine, morphine-6-glucuronide (M6G), morphine-3-glucuronide (M3G) and normorphine were analysed with high performance liquid chromatography in plasma and urine, collected over 72 h after administration of single intravenous 5 mg and oral 20 mg doses of morphine to 7 healthy volunteers. Systemic p...
Gespeichert in:
Veröffentlicht in: | Clinical pharmacokinetics 1993-04, Vol.24 (4), p.344-354 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 354 |
---|---|
container_issue | 4 |
container_start_page | 344 |
container_title | Clinical pharmacokinetics |
container_volume | 24 |
creator | HASSLESTRÖM, J SÄWE, J |
description | Morphine, morphine-6-glucuronide (M6G), morphine-3-glucuronide (M3G) and normorphine were analysed with high performance liquid chromatography in plasma and urine, collected over 72 h after administration of single intravenous 5 mg and oral 20 mg doses of morphine to 7 healthy volunteers. Systemic plasma clearance of morphine was on average 21.1 +/- 3.4 ml/min/kg (1.27 +/- 0.20 L/h/kg), volume of distribution was 2.9 +/- 0.8 L/kg and oral bioavailability was 29.2 +/- 7.2%. Clearance of morphine to form M3G and M6G comprised 57.3% and 10.4%, respectively, and renal clearance comprised 10.9% of total systemic plasma clearance; hence, more than one-fifth of a dose (20.8%) remained as unidentified residual clearance. On the basis of the area under the plasma concentration-time curves determined after oral and intravenous administration, the ratios of M6G:morphine were 3.6 +/- 1.2 and 0.7 +/- 0.3, respectively. The corresponding figures for M3G:morphine were 29.9 +/- 6.8 and 7.7 +/- 1.4. Differences in metabolic ratios between the parenteral and oral routes could be attributed solely to differences in morphine concentrations as evidenced both by plasma concentrations and amounts excreted in urine. An oral:parenteral potency ratio of 1:3 may, thus, be due to differences in circulating amounts of morphine since the proportions of an administered dose found as M6G and M3G after administration by both routes were equal. A major finding was a slowly declining terminal phase of morphine and metabolites that was evident both in plasma and in urinary excretion versus time curves, where the half-lives of morphine, M3G and M6G were 15.1 +/- 6.5 h, 11.2 +/- 2.7 h and 12.9 +/- 4.5 h, respectively. The terminal half-life of normorphine was 23.9 +/- 10.1 h after oral administration. Comparison of oral with intravenous excretion curves showed that a greater part of morphine and metabolites were excreted during the slowly declining phase after the oral dose than the intravenous dose, which is highly suggestive of enterohepatic cycling. The renal clearance of M6G and morphine was seen to exceed creatinine clearance, possibly due to an active secretion process. |
doi_str_mv | 10.2165/00003088-199324040-00007 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_75731267</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>75731267</sourcerecordid><originalsourceid>FETCH-LOGICAL-c308t-55ee3f435b85f132eb3be557c6b77d33f689380b9ee23c6d60b845e156f794283</originalsourceid><addsrcrecordid>eNo9kc1u3CAUhVGVKpmmfYRKLKLs3IIxf9lVUfojpeqmXVuArzskNjiAK-U5-sLFk-mwQZz73QOXgxCm5ENLBf9I6mJEqYZqzdqOdKTZJPkK7SiVusqtOEM7wmjbcC3YBXqT80MlVEvIOTpXnaZEkB36-z2mZe8D4GVv0mxcfKyH4l3GJgx4hmJsnHyesQ94v84mZHyDIRRIcQ-LqSR2z27y4fehIcFUtT-AXQwlebsWHwOO48mpQMYlYuMOVFx89MMGu-qZzEbnt-j1aKYM7477Jfr1-e7n7dfm_seXb7ef7htXRy8N5wBs7Bi3io-UtWCZBc6lE1bKgbFRKM0UsRqgZU4MgljVcaBcjFJ3rWKX6PrFd0nxaYVc-tlnB9NkAsQ195LL-n9CVlC9gC7FnBOM_ZL8bNJzT0m_5dH_z6M_5XGQttb3xztWO8NwajwGUOtXx7rJzkxjMsH5fMK6OoOuL_gH3XSWLA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>75731267</pqid></control><display><type>article</type><title>Morphine pharmacokinetics and metabolism in humans : enterohepatic cycling and relative contribution of metabolites to active opioid concentrations</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>HASSLESTRÖM, J ; SÄWE, J</creator><creatorcontrib>HASSLESTRÖM, J ; SÄWE, J</creatorcontrib><description>Morphine, morphine-6-glucuronide (M6G), morphine-3-glucuronide (M3G) and normorphine were analysed with high performance liquid chromatography in plasma and urine, collected over 72 h after administration of single intravenous 5 mg and oral 20 mg doses of morphine to 7 healthy volunteers. Systemic plasma clearance of morphine was on average 21.1 +/- 3.4 ml/min/kg (1.27 +/- 0.20 L/h/kg), volume of distribution was 2.9 +/- 0.8 L/kg and oral bioavailability was 29.2 +/- 7.2%. Clearance of morphine to form M3G and M6G comprised 57.3% and 10.4%, respectively, and renal clearance comprised 10.9% of total systemic plasma clearance; hence, more than one-fifth of a dose (20.8%) remained as unidentified residual clearance. On the basis of the area under the plasma concentration-time curves determined after oral and intravenous administration, the ratios of M6G:morphine were 3.6 +/- 1.2 and 0.7 +/- 0.3, respectively. The corresponding figures for M3G:morphine were 29.9 +/- 6.8 and 7.7 +/- 1.4. Differences in metabolic ratios between the parenteral and oral routes could be attributed solely to differences in morphine concentrations as evidenced both by plasma concentrations and amounts excreted in urine. An oral:parenteral potency ratio of 1:3 may, thus, be due to differences in circulating amounts of morphine since the proportions of an administered dose found as M6G and M3G after administration by both routes were equal. A major finding was a slowly declining terminal phase of morphine and metabolites that was evident both in plasma and in urinary excretion versus time curves, where the half-lives of morphine, M3G and M6G were 15.1 +/- 6.5 h, 11.2 +/- 2.7 h and 12.9 +/- 4.5 h, respectively. The terminal half-life of normorphine was 23.9 +/- 10.1 h after oral administration. Comparison of oral with intravenous excretion curves showed that a greater part of morphine and metabolites were excreted during the slowly declining phase after the oral dose than the intravenous dose, which is highly suggestive of enterohepatic cycling. The renal clearance of M6G and morphine was seen to exceed creatinine clearance, possibly due to an active secretion process.</description><identifier>ISSN: 0312-5963</identifier><identifier>EISSN: 1179-1926</identifier><identifier>DOI: 10.2165/00003088-199324040-00007</identifier><identifier>PMID: 8491060</identifier><identifier>CODEN: CPKNDH</identifier><language>eng</language><publisher>Auckland: Adis international</publisher><subject>Administration, Oral ; Adult ; Analgesics ; Biological and medical sciences ; Enterohepatic Circulation - physiology ; Female ; Humans ; Injections, Intravenous ; Male ; Medical sciences ; Middle Aged ; Morphine - administration & dosage ; Morphine - metabolism ; Morphine - pharmacokinetics ; Morphine Derivatives - administration & dosage ; Morphine Derivatives - metabolism ; Morphine Derivatives - pharmacokinetics ; Neuropharmacology ; Pharmacology. Drug treatments</subject><ispartof>Clinical pharmacokinetics, 1993-04, Vol.24 (4), p.344-354</ispartof><rights>1993 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4689967$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/8491060$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>HASSLESTRÖM, J</creatorcontrib><creatorcontrib>SÄWE, J</creatorcontrib><title>Morphine pharmacokinetics and metabolism in humans : enterohepatic cycling and relative contribution of metabolites to active opioid concentrations</title><title>Clinical pharmacokinetics</title><addtitle>Clin Pharmacokinet</addtitle><description>Morphine, morphine-6-glucuronide (M6G), morphine-3-glucuronide (M3G) and normorphine were analysed with high performance liquid chromatography in plasma and urine, collected over 72 h after administration of single intravenous 5 mg and oral 20 mg doses of morphine to 7 healthy volunteers. Systemic plasma clearance of morphine was on average 21.1 +/- 3.4 ml/min/kg (1.27 +/- 0.20 L/h/kg), volume of distribution was 2.9 +/- 0.8 L/kg and oral bioavailability was 29.2 +/- 7.2%. Clearance of morphine to form M3G and M6G comprised 57.3% and 10.4%, respectively, and renal clearance comprised 10.9% of total systemic plasma clearance; hence, more than one-fifth of a dose (20.8%) remained as unidentified residual clearance. On the basis of the area under the plasma concentration-time curves determined after oral and intravenous administration, the ratios of M6G:morphine were 3.6 +/- 1.2 and 0.7 +/- 0.3, respectively. The corresponding figures for M3G:morphine were 29.9 +/- 6.8 and 7.7 +/- 1.4. Differences in metabolic ratios between the parenteral and oral routes could be attributed solely to differences in morphine concentrations as evidenced both by plasma concentrations and amounts excreted in urine. An oral:parenteral potency ratio of 1:3 may, thus, be due to differences in circulating amounts of morphine since the proportions of an administered dose found as M6G and M3G after administration by both routes were equal. A major finding was a slowly declining terminal phase of morphine and metabolites that was evident both in plasma and in urinary excretion versus time curves, where the half-lives of morphine, M3G and M6G were 15.1 +/- 6.5 h, 11.2 +/- 2.7 h and 12.9 +/- 4.5 h, respectively. The terminal half-life of normorphine was 23.9 +/- 10.1 h after oral administration. Comparison of oral with intravenous excretion curves showed that a greater part of morphine and metabolites were excreted during the slowly declining phase after the oral dose than the intravenous dose, which is highly suggestive of enterohepatic cycling. The renal clearance of M6G and morphine was seen to exceed creatinine clearance, possibly due to an active secretion process.</description><subject>Administration, Oral</subject><subject>Adult</subject><subject>Analgesics</subject><subject>Biological and medical sciences</subject><subject>Enterohepatic Circulation - physiology</subject><subject>Female</subject><subject>Humans</subject><subject>Injections, Intravenous</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Morphine - administration & dosage</subject><subject>Morphine - metabolism</subject><subject>Morphine - pharmacokinetics</subject><subject>Morphine Derivatives - administration & dosage</subject><subject>Morphine Derivatives - metabolism</subject><subject>Morphine Derivatives - pharmacokinetics</subject><subject>Neuropharmacology</subject><subject>Pharmacology. Drug treatments</subject><issn>0312-5963</issn><issn>1179-1926</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1993</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kc1u3CAUhVGVKpmmfYRKLKLs3IIxf9lVUfojpeqmXVuArzskNjiAK-U5-sLFk-mwQZz73QOXgxCm5ENLBf9I6mJEqYZqzdqOdKTZJPkK7SiVusqtOEM7wmjbcC3YBXqT80MlVEvIOTpXnaZEkB36-z2mZe8D4GVv0mxcfKyH4l3GJgx4hmJsnHyesQ94v84mZHyDIRRIcQ-LqSR2z27y4fehIcFUtT-AXQwlebsWHwOO48mpQMYlYuMOVFx89MMGu-qZzEbnt-j1aKYM7477Jfr1-e7n7dfm_seXb7ef7htXRy8N5wBs7Bi3io-UtWCZBc6lE1bKgbFRKM0UsRqgZU4MgljVcaBcjFJ3rWKX6PrFd0nxaYVc-tlnB9NkAsQ195LL-n9CVlC9gC7FnBOM_ZL8bNJzT0m_5dH_z6M_5XGQttb3xztWO8NwajwGUOtXx7rJzkxjMsH5fMK6OoOuL_gH3XSWLA</recordid><startdate>19930401</startdate><enddate>19930401</enddate><creator>HASSLESTRÖM, J</creator><creator>SÄWE, J</creator><general>Adis international</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19930401</creationdate><title>Morphine pharmacokinetics and metabolism in humans : enterohepatic cycling and relative contribution of metabolites to active opioid concentrations</title><author>HASSLESTRÖM, J ; SÄWE, J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c308t-55ee3f435b85f132eb3be557c6b77d33f689380b9ee23c6d60b845e156f794283</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1993</creationdate><topic>Administration, Oral</topic><topic>Adult</topic><topic>Analgesics</topic><topic>Biological and medical sciences</topic><topic>Enterohepatic Circulation - physiology</topic><topic>Female</topic><topic>Humans</topic><topic>Injections, Intravenous</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Morphine - administration & dosage</topic><topic>Morphine - metabolism</topic><topic>Morphine - pharmacokinetics</topic><topic>Morphine Derivatives - administration & dosage</topic><topic>Morphine Derivatives - metabolism</topic><topic>Morphine Derivatives - pharmacokinetics</topic><topic>Neuropharmacology</topic><topic>Pharmacology. Drug treatments</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>HASSLESTRÖM, J</creatorcontrib><creatorcontrib>SÄWE, J</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical pharmacokinetics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>HASSLESTRÖM, J</au><au>SÄWE, J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Morphine pharmacokinetics and metabolism in humans : enterohepatic cycling and relative contribution of metabolites to active opioid concentrations</atitle><jtitle>Clinical pharmacokinetics</jtitle><addtitle>Clin Pharmacokinet</addtitle><date>1993-04-01</date><risdate>1993</risdate><volume>24</volume><issue>4</issue><spage>344</spage><epage>354</epage><pages>344-354</pages><issn>0312-5963</issn><eissn>1179-1926</eissn><coden>CPKNDH</coden><abstract>Morphine, morphine-6-glucuronide (M6G), morphine-3-glucuronide (M3G) and normorphine were analysed with high performance liquid chromatography in plasma and urine, collected over 72 h after administration of single intravenous 5 mg and oral 20 mg doses of morphine to 7 healthy volunteers. Systemic plasma clearance of morphine was on average 21.1 +/- 3.4 ml/min/kg (1.27 +/- 0.20 L/h/kg), volume of distribution was 2.9 +/- 0.8 L/kg and oral bioavailability was 29.2 +/- 7.2%. Clearance of morphine to form M3G and M6G comprised 57.3% and 10.4%, respectively, and renal clearance comprised 10.9% of total systemic plasma clearance; hence, more than one-fifth of a dose (20.8%) remained as unidentified residual clearance. On the basis of the area under the plasma concentration-time curves determined after oral and intravenous administration, the ratios of M6G:morphine were 3.6 +/- 1.2 and 0.7 +/- 0.3, respectively. The corresponding figures for M3G:morphine were 29.9 +/- 6.8 and 7.7 +/- 1.4. Differences in metabolic ratios between the parenteral and oral routes could be attributed solely to differences in morphine concentrations as evidenced both by plasma concentrations and amounts excreted in urine. An oral:parenteral potency ratio of 1:3 may, thus, be due to differences in circulating amounts of morphine since the proportions of an administered dose found as M6G and M3G after administration by both routes were equal. A major finding was a slowly declining terminal phase of morphine and metabolites that was evident both in plasma and in urinary excretion versus time curves, where the half-lives of morphine, M3G and M6G were 15.1 +/- 6.5 h, 11.2 +/- 2.7 h and 12.9 +/- 4.5 h, respectively. The terminal half-life of normorphine was 23.9 +/- 10.1 h after oral administration. Comparison of oral with intravenous excretion curves showed that a greater part of morphine and metabolites were excreted during the slowly declining phase after the oral dose than the intravenous dose, which is highly suggestive of enterohepatic cycling. The renal clearance of M6G and morphine was seen to exceed creatinine clearance, possibly due to an active secretion process.</abstract><cop>Auckland</cop><pub>Adis international</pub><pmid>8491060</pmid><doi>10.2165/00003088-199324040-00007</doi><tpages>11</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0312-5963 |
ispartof | Clinical pharmacokinetics, 1993-04, Vol.24 (4), p.344-354 |
issn | 0312-5963 1179-1926 |
language | eng |
recordid | cdi_proquest_miscellaneous_75731267 |
source | MEDLINE; SpringerLink Journals - AutoHoldings |
subjects | Administration, Oral Adult Analgesics Biological and medical sciences Enterohepatic Circulation - physiology Female Humans Injections, Intravenous Male Medical sciences Middle Aged Morphine - administration & dosage Morphine - metabolism Morphine - pharmacokinetics Morphine Derivatives - administration & dosage Morphine Derivatives - metabolism Morphine Derivatives - pharmacokinetics Neuropharmacology Pharmacology. Drug treatments |
title | Morphine pharmacokinetics and metabolism in humans : enterohepatic cycling and relative contribution of metabolites to active opioid concentrations |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T05%3A19%3A34IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Morphine%20pharmacokinetics%20and%20metabolism%20in%20humans%20:%20enterohepatic%20cycling%20and%20relative%20contribution%20of%20metabolites%20to%20active%20opioid%20concentrations&rft.jtitle=Clinical%20pharmacokinetics&rft.au=HASSLESTR%C3%96M,%20J&rft.date=1993-04-01&rft.volume=24&rft.issue=4&rft.spage=344&rft.epage=354&rft.pages=344-354&rft.issn=0312-5963&rft.eissn=1179-1926&rft.coden=CPKNDH&rft_id=info:doi/10.2165/00003088-199324040-00007&rft_dat=%3Cproquest_cross%3E75731267%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=75731267&rft_id=info:pmid/8491060&rfr_iscdi=true |